Skip to main content

Table 2 Overall baseline characteristics according to liver disease stage

From: Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Parameters Cirrhosis (n = 731) Advanced liver fibrosis (n = 254)
Sex, n (%)
 M 391 (53.5) 152 (59.8)
 F 340 (46.5) 102 (40.2)
Age, years, median [IQR] 68 [60–74] 66 [58–72]
BMI, kg/m2, median [IQR] 26 [23.9–28.4] 26.1 [24.1–28.3]
Diabetes, n (%) 99 (13.6) 32 (12.6)
Metabolic syndrome, n (%) 53 (8.2) 16 (7.5)
Child–Turcotte–Pugh, n (%)
 Class A 649 (88.8)
 Class B 82 (11.2)
HCV genotype, n (%)
 1 561 (76.7) 205 (80.7)
 2 121 (16.6) 38 (15)
 3 43 (5.9) 7 (2.8)
 4 6 (0.8) 4 (1.6)
Liver stiffness, kPa, median [IQR] 21 [15.6–27.2] 10.7 [10–11.8]
Treatment duration, n (%) (weeks)
 12 401 (54.9) 211 (83.1)
 24 330 (45.1) 43 (16.9)
SVR12, n (%) 714 (97.7) 252 (99.2)
DAAs regimen, n (%)
 SOF/RBV 322 (44) 96 (37.8)
 SOF/LDV ± RBV 158 (21.6) 31 (12.2)
 SOF/DCV ± RBV 26 (3.6) 7 (2.8)
 SOF/SIM ± RBV 78 (10.7) 21 (8.3)
 2D/3D ± RBV 147 (20.1) 109 (39)
Treatment classes, n (%)
 SOF based 584 (79.9) 154 (60.6)
 RBV included 549 (75.1) 156 (24.2)
 SOF/RBV 450 (61.6) 123 (48.4)
HCC occurrence, n (%) 35 (4.8) 0 (0)
\